 Todd Kingdom
Concepts (344)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Sinusitis | 24 | 2021 | 174 | 3.900 |
Why?
| | Rhinitis | 22 | 2023 | 128 | 3.550 |
Why?
| | Nasal Polyps | 15 | 2017 | 49 | 3.240 |
Why?
| | Endoscopy | 19 | 2023 | 246 | 2.730 |
Why?
| | Paranasal Sinuses | 13 | 2017 | 66 | 2.030 |
Why?
| | Dacryocystorhinostomy | 3 | 2020 | 10 | 1.130 |
Why?
| | Surgery, Computer-Assisted | 3 | 2015 | 62 | 1.070 |
Why?
| | Nasal Mucosa | 6 | 2019 | 93 | 1.030 |
Why?
| | Paranasal Sinus Neoplasms | 5 | 2024 | 17 | 1.000 |
Why?
| | Skull Base | 6 | 2023 | 39 | 0.950 |
Why?
| | Aspirin | 6 | 2016 | 324 | 0.940 |
Why?
| | Orbit | 4 | 2016 | 59 | 0.740 |
Why?
| | Cystic Fibrosis | 6 | 2014 | 955 | 0.730 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 3 | 2015 | 299 | 0.630 |
Why?
| | Lipoxygenase | 2 | 2008 | 12 | 0.580 |
Why?
| | Postoperative Complications | 6 | 2018 | 2128 | 0.580 |
Why?
| | Chronic Disease | 18 | 2023 | 1578 | 0.560 |
Why?
| | Sphenoid Sinus | 2 | 2009 | 8 | 0.560 |
Why?
| | Asthma, Aspirin-Induced | 1 | 2015 | 1 | 0.510 |
Why?
| | Decompression, Surgical | 2 | 2017 | 93 | 0.500 |
Why?
| | Graves Ophthalmopathy | 1 | 2015 | 14 | 0.490 |
Why?
| | Paranasal Sinus Diseases | 3 | 2017 | 14 | 0.470 |
Why?
| | Protein Array Analysis | 2 | 2011 | 56 | 0.410 |
Why?
| | Eosinophilia | 3 | 2016 | 186 | 0.400 |
Why?
| | Respiratory System | 1 | 2013 | 137 | 0.400 |
Why?
| | Bronchiectasis | 1 | 2013 | 106 | 0.400 |
Why?
| | Tomography, X-Ray Computed | 15 | 2018 | 2286 | 0.390 |
Why?
| | Middle Aged | 30 | 2019 | 26737 | 0.390 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2011 | 25 | 0.380 |
Why?
| | Immunotherapy | 1 | 2015 | 474 | 0.380 |
Why?
| | Proto-Oncogene Proteins c-bcl-2 | 1 | 2012 | 213 | 0.380 |
Why?
| | Sputum | 1 | 2013 | 285 | 0.380 |
Why?
| | Rhinitis, Allergic | 4 | 2021 | 35 | 0.370 |
Why?
| | Chemokine CCL5 | 1 | 2011 | 45 | 0.370 |
Why?
| | Matrix Metalloproteinase 9 | 1 | 2011 | 119 | 0.370 |
Why?
| | Humans | 68 | 2024 | 114696 | 0.360 |
Why?
| | Evidence-Based Medicine | 5 | 2016 | 668 | 0.350 |
Why?
| | Cyclooxygenase 1 | 2 | 2008 | 20 | 0.350 |
Why?
| | Frontal Sinus | 2 | 2007 | 4 | 0.340 |
Why?
| | Retrospective Studies | 22 | 2022 | 12554 | 0.340 |
Why?
| | Surgical Flaps | 3 | 2019 | 121 | 0.340 |
Why?
| | Cerebrospinal Fluid Rhinorrhea | 3 | 2022 | 7 | 0.340 |
Why?
| | Leiomyosarcoma | 1 | 2009 | 26 | 0.330 |
Why?
| | Adult | 29 | 2019 | 30552 | 0.330 |
Why?
| | Cyclooxygenase 2 | 2 | 2008 | 164 | 0.320 |
Why?
| | Mycoses | 3 | 2005 | 67 | 0.320 |
Why?
| | Head and Neck Neoplasms | 3 | 2024 | 427 | 0.310 |
Why?
| | Odontoma | 1 | 2008 | 4 | 0.310 |
Why?
| | Maxillary Sinus Neoplasms | 1 | 2008 | 7 | 0.310 |
Why?
| | Prostaglandin-Endoperoxide Synthases | 1 | 2008 | 58 | 0.310 |
Why?
| | Male | 37 | 2023 | 55604 | 0.300 |
Why?
| | Aged | 22 | 2019 | 19074 | 0.290 |
Why?
| | Immunoglobulin E | 2 | 2018 | 314 | 0.290 |
Why?
| | Female | 34 | 2023 | 59518 | 0.270 |
Why?
| | Treatment Outcome | 12 | 2023 | 9088 | 0.270 |
Why?
| | Lymphoma, Non-Hodgkin | 1 | 2007 | 71 | 0.260 |
Why?
| | Practice Guidelines as Topic | 2 | 2014 | 1395 | 0.260 |
Why?
| | Nose Neoplasms | 2 | 1996 | 15 | 0.260 |
Why?
| | Consensus | 3 | 2021 | 537 | 0.260 |
Why?
| | Osteomyelitis | 1 | 2007 | 105 | 0.250 |
Why?
| | Cranial Fossa, Posterior | 2 | 2012 | 16 | 0.250 |
Why?
| | Antibiotic Prophylaxis | 2 | 2016 | 96 | 0.240 |
Why?
| | Streptococcus | 1 | 2004 | 22 | 0.230 |
Why?
| | Prednisone | 2 | 2017 | 229 | 0.230 |
Why?
| | Hypersensitivity | 3 | 2024 | 252 | 0.230 |
Why?
| | Gram-Negative Bacteria | 1 | 2004 | 66 | 0.230 |
Why?
| | Staphylococcus | 1 | 2004 | 69 | 0.230 |
Why?
| | Otorhinolaryngologic Surgical Procedures | 4 | 2011 | 33 | 0.230 |
Why?
| | Adenoma | 2 | 2018 | 189 | 0.220 |
Why?
| | Otorhinolaryngologic Diseases | 1 | 2003 | 13 | 0.220 |
Why?
| | Skull Base Neoplasms | 1 | 2023 | 24 | 0.220 |
Why?
| | Bone Diseases | 1 | 2003 | 57 | 0.210 |
Why?
| | Reoperation | 3 | 2019 | 514 | 0.200 |
Why?
| | Aged, 80 and over | 10 | 2018 | 6347 | 0.200 |
Why?
| | Pseudomonas aeruginosa | 4 | 2014 | 298 | 0.200 |
Why?
| | Adolescent | 13 | 2019 | 17853 | 0.190 |
Why?
| | Laryngeal Diseases | 2 | 2003 | 21 | 0.190 |
Why?
| | Glucocorticoids | 2 | 2017 | 532 | 0.180 |
Why?
| | Lacrimal Duct Obstruction | 1 | 2020 | 4 | 0.180 |
Why?
| | Nasolacrimal Duct | 1 | 2020 | 7 | 0.180 |
Why?
| | Diagnosis, Differential | 4 | 2018 | 1342 | 0.170 |
Why?
| | Otolaryngology | 2 | 2011 | 69 | 0.160 |
Why?
| | Nasal Septum | 2 | 2020 | 16 | 0.160 |
Why?
| | Sphenoid Sinusitis | 1 | 2018 | 4 | 0.160 |
Why?
| | Sella Turcica | 1 | 2018 | 13 | 0.160 |
Why?
| | Polyethylenes | 1 | 2018 | 15 | 0.160 |
Why?
| | Up-Regulation | 2 | 2012 | 808 | 0.160 |
Why?
| | Parotid Diseases | 1 | 1998 | 4 | 0.160 |
Why?
| | Ethmoid Sinus | 2 | 2015 | 7 | 0.160 |
Why?
| | Sclerosing Solutions | 1 | 1998 | 9 | 0.160 |
Why?
| | Sclerotherapy | 1 | 1998 | 19 | 0.150 |
Why?
| | Vision Disorders | 2 | 2017 | 130 | 0.150 |
Why?
| | Doxycycline | 1 | 1998 | 55 | 0.150 |
Why?
| | Immunohistochemistry | 3 | 2009 | 1629 | 0.150 |
Why?
| | Melanoma | 2 | 1995 | 620 | 0.150 |
Why?
| | Immunoglobulin D | 1 | 2017 | 27 | 0.150 |
Why?
| | Cysts | 1 | 1998 | 93 | 0.150 |
Why?
| | Follow-Up Studies | 4 | 2015 | 4411 | 0.140 |
Why?
| | Mucocele | 1 | 2017 | 11 | 0.140 |
Why?
| | Prostheses and Implants | 1 | 2018 | 137 | 0.140 |
Why?
| | Pituitary Neoplasms | 1 | 2018 | 157 | 0.140 |
Why?
| | Visual Acuity | 2 | 2017 | 274 | 0.140 |
Why?
| | Aspergillus fumigatus | 1 | 1996 | 20 | 0.130 |
Why?
| | Young Adult | 8 | 2018 | 10471 | 0.130 |
Why?
| | Aspergillosis | 1 | 1996 | 23 | 0.130 |
Why?
| | Neuroendoscopy | 1 | 2016 | 14 | 0.130 |
Why?
| | Rhinitis, Allergic, Perennial | 2 | 2013 | 23 | 0.130 |
Why?
| | Therapeutic Irrigation | 1 | 2016 | 67 | 0.130 |
Why?
| | Graves Disease | 1 | 2016 | 32 | 0.130 |
Why?
| | Th1-Th2 Balance | 1 | 2015 | 9 | 0.130 |
Why?
| | Superantigens | 1 | 2015 | 69 | 0.130 |
Why?
| | Pharynx | 1 | 1995 | 49 | 0.120 |
Why?
| | Mouth | 1 | 1995 | 70 | 0.120 |
Why?
| | Forced Expiratory Volume | 2 | 2014 | 475 | 0.120 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 1996 | 116 | 0.120 |
Why?
| | Nasopharynx | 1 | 2015 | 61 | 0.120 |
Why?
| | Neck | 3 | 2005 | 85 | 0.120 |
Why?
| | Biocompatible Materials | 1 | 2018 | 369 | 0.120 |
Why?
| | Nasal Cavity | 1 | 1995 | 47 | 0.120 |
Why?
| | Intraoperative Complications | 1 | 2016 | 122 | 0.120 |
Why?
| | Meningitis | 1 | 2016 | 74 | 0.120 |
Why?
| | Dinoprostone | 1 | 2015 | 184 | 0.120 |
Why?
| | Actinomycosis | 1 | 1994 | 3 | 0.120 |
Why?
| | Neurosurgical Procedures | 1 | 2016 | 152 | 0.120 |
Why?
| | Cervical Vertebrae | 1 | 1995 | 104 | 0.120 |
Why?
| | Microbiota | 3 | 2018 | 647 | 0.120 |
Why?
| | Radiotherapy, Adjuvant | 1 | 1995 | 182 | 0.120 |
Why?
| | Case-Control Studies | 5 | 2017 | 3003 | 0.120 |
Why?
| | Nose Diseases | 1 | 1994 | 11 | 0.120 |
Why?
| | T-Lymphocytes, Regulatory | 1 | 2017 | 339 | 0.110 |
Why?
| | Angiofibroma | 1 | 2013 | 3 | 0.110 |
Why?
| | Nasopharyngeal Neoplasms | 1 | 2013 | 13 | 0.110 |
Why?
| | Pituitary Diseases | 1 | 2013 | 22 | 0.110 |
Why?
| | Cerebellopontine Angle | 1 | 1993 | 6 | 0.110 |
Why?
| | HIV Seropositivity | 1 | 1994 | 109 | 0.110 |
Why?
| | Granulocytes | 1 | 2013 | 77 | 0.110 |
Why?
| | Biopsy | 3 | 2017 | 1036 | 0.110 |
Why?
| | Biofilms | 1 | 2015 | 223 | 0.110 |
Why?
| | Prospective Studies | 3 | 2012 | 6220 | 0.110 |
Why?
| | Transforming Growth Factor beta | 1 | 2015 | 448 | 0.100 |
Why?
| | bcl-X Protein | 1 | 2012 | 38 | 0.100 |
Why?
| | Chemoreceptor Cells | 1 | 2013 | 55 | 0.100 |
Why?
| | Vital Capacity | 1 | 2013 | 255 | 0.100 |
Why?
| | Microarray Analysis | 1 | 2012 | 118 | 0.100 |
Why?
| | Cerebrospinal Fluid Leak | 3 | 2022 | 28 | 0.100 |
Why?
| | TRPM Cation Channels | 1 | 2013 | 67 | 0.100 |
Why?
| | Neoplasms, Second Primary | 2 | 2012 | 92 | 0.100 |
Why?
| | Skull Neoplasms | 1 | 2012 | 22 | 0.100 |
Why?
| | Neoplasm Recurrence, Local | 2 | 2013 | 858 | 0.100 |
Why?
| | Neovascularization, Pathologic | 1 | 2013 | 281 | 0.100 |
Why?
| | Cerebellar Neoplasms | 1 | 1993 | 130 | 0.100 |
Why?
| | Histocytochemistry | 1 | 2011 | 78 | 0.100 |
Why?
| | Incidence | 2 | 2015 | 2313 | 0.090 |
Why?
| | Cystic Fibrosis Transmembrane Conductance Regulator | 1 | 2014 | 287 | 0.090 |
Why?
| | Pituitary Gland | 1 | 2012 | 148 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 6 | 2013 | 3053 | 0.090 |
Why?
| | Vasoconstrictor Agents | 1 | 2011 | 112 | 0.090 |
Why?
| | Bacteria | 1 | 2016 | 725 | 0.080 |
Why?
| | Microscopy, Fluorescence | 1 | 2011 | 396 | 0.080 |
Why?
| | Adaptor Protein Complex beta Subunits | 1 | 2009 | 1 | 0.080 |
Why?
| | Caspase 8 | 1 | 2009 | 43 | 0.080 |
Why?
| | Caspase 9 | 1 | 2009 | 48 | 0.080 |
Why?
| | Biopsy, Needle | 1 | 2009 | 182 | 0.080 |
Why?
| | Drug Tolerance | 1 | 2009 | 79 | 0.080 |
Why?
| | HSP70 Heat-Shock Proteins | 1 | 2009 | 61 | 0.080 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 1 | 2011 | 797 | 0.080 |
Why?
| | Arachidonate 12-Lipoxygenase | 1 | 2008 | 13 | 0.080 |
Why?
| | Arachidonate 15-Lipoxygenase | 1 | 2008 | 16 | 0.080 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2008 | 45 | 0.080 |
Why?
| | Fellowships and Scholarships | 1 | 2011 | 227 | 0.080 |
Why?
| | Blotting, Western | 1 | 2011 | 1147 | 0.080 |
Why?
| | Maxilla | 1 | 2007 | 29 | 0.070 |
Why?
| | Databases as Topic | 1 | 2007 | 63 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2011 | 368 | 0.070 |
Why?
| | Quality of Life | 3 | 2024 | 2353 | 0.070 |
Why?
| | Reference Values | 1 | 2008 | 743 | 0.070 |
Why?
| | Arnold-Chiari Malformation | 2 | 1997 | 30 | 0.070 |
Why?
| | Child | 8 | 2016 | 18420 | 0.070 |
Why?
| | Anti-Bacterial Agents | 1 | 2015 | 1481 | 0.070 |
Why?
| | Disease Progression | 1 | 2012 | 2380 | 0.060 |
Why?
| | Statistics, Nonparametric | 1 | 2006 | 385 | 0.060 |
Why?
| | Linear Models | 1 | 2007 | 768 | 0.060 |
Why?
| | Risk Assessment | 2 | 2013 | 2968 | 0.060 |
Why?
| | Asthma | 2 | 2016 | 2029 | 0.060 |
Why?
| | HIV Infections | 1 | 1998 | 2469 | 0.060 |
Why?
| | Child, Preschool | 4 | 2011 | 9118 | 0.060 |
Why?
| | Mutation | 1 | 2014 | 3346 | 0.060 |
Why?
| | United States | 3 | 2015 | 12185 | 0.060 |
Why?
| | Fungi | 1 | 2005 | 124 | 0.060 |
Why?
| | Pharyngeal Diseases | 1 | 2003 | 12 | 0.050 |
Why?
| | Drug Resistance, Bacterial | 1 | 2004 | 155 | 0.050 |
Why?
| | Stroke | 1 | 2012 | 1022 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2004 | 300 | 0.050 |
Why?
| | Streptococcus pneumoniae | 1 | 2004 | 133 | 0.050 |
Why?
| | Mouth Diseases | 1 | 2003 | 40 | 0.050 |
Why?
| | Acute Disease | 2 | 2016 | 911 | 0.050 |
Why?
| | Head | 1 | 2003 | 85 | 0.050 |
Why?
| | Antifungal Agents | 1 | 2003 | 128 | 0.050 |
Why?
| | Predictive Value of Tests | 1 | 2007 | 1796 | 0.050 |
Why?
| | Equipment Design | 1 | 2004 | 508 | 0.050 |
Why?
| | Vocal Cord Paralysis | 2 | 1998 | 21 | 0.050 |
Why?
| | Immunocompromised Host | 1 | 2003 | 195 | 0.050 |
Why?
| | Postoperative Period | 1 | 2022 | 289 | 0.050 |
Why?
| | Staphylococcus aureus | 1 | 2004 | 389 | 0.050 |
Why?
| | Elective Surgical Procedures | 1 | 2022 | 151 | 0.050 |
Why?
| | Mitomycin | 1 | 2020 | 27 | 0.050 |
Why?
| | Genotype | 2 | 2014 | 1760 | 0.040 |
Why?
| | Radiographic Image Interpretation, Computer-Assisted | 1 | 2001 | 98 | 0.040 |
Why?
| | Absorbable Implants | 1 | 2020 | 34 | 0.040 |
Why?
| | Drug Implants | 1 | 2020 | 70 | 0.040 |
Why?
| | Meningioma | 1 | 2001 | 77 | 0.040 |
Why?
| | Signal Transduction | 1 | 2012 | 4515 | 0.040 |
Why?
| | Hypopharyngeal Neoplasms | 1 | 1998 | 2 | 0.040 |
Why?
| | Tracheal Neoplasms | 1 | 1998 | 11 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2000 | 218 | 0.040 |
Why?
| | Laryngeal Neoplasms | 1 | 1998 | 27 | 0.040 |
Why?
| | Nasal Decongestants | 1 | 2018 | 8 | 0.040 |
Why?
| | Larynx | 1 | 1998 | 47 | 0.040 |
Why?
| | Histamine Antagonists | 1 | 2018 | 20 | 0.040 |
Why?
| | Tertiary Care Centers | 1 | 2018 | 126 | 0.040 |
Why?
| | Syndecan-1 | 1 | 2017 | 27 | 0.040 |
Why?
| | Epidemiologic Methods | 1 | 2018 | 72 | 0.040 |
Why?
| | Skin Tests | 1 | 2018 | 116 | 0.040 |
Why?
| | Epistaxis | 2 | 2011 | 11 | 0.040 |
Why?
| | Probiotics | 1 | 2018 | 46 | 0.040 |
Why?
| | Mucus | 1 | 2017 | 54 | 0.040 |
Why?
| | Plasma Cells | 1 | 2017 | 56 | 0.040 |
Why?
| | Length of Stay | 1 | 2022 | 962 | 0.040 |
Why?
| | Complementary Therapies | 1 | 2018 | 72 | 0.040 |
Why?
| | Severity of Illness Index | 2 | 2016 | 2540 | 0.040 |
Why?
| | Carcinoma | 1 | 1998 | 198 | 0.030 |
Why?
| | Physical Examination | 1 | 2018 | 222 | 0.030 |
Why?
| | Neoplasm Invasiveness | 2 | 2013 | 442 | 0.030 |
Why?
| | Immunoglobulin A | 1 | 2017 | 166 | 0.030 |
Why?
| | Occupational Diseases | 1 | 2018 | 128 | 0.030 |
Why?
| | Candidiasis | 1 | 1996 | 51 | 0.030 |
Why?
| | Immunoglobulin M | 1 | 2017 | 246 | 0.030 |
Why?
| | Perioperative Period | 1 | 2016 | 49 | 0.030 |
Why?
| | Forkhead Transcription Factors | 1 | 2017 | 170 | 0.030 |
Why?
| | Chondrocalcinosis | 1 | 1995 | 2 | 0.030 |
Why?
| | Ossification of Posterior Longitudinal Ligament | 1 | 1995 | 2 | 0.030 |
Why?
| | Giant Cell Tumors | 1 | 1995 | 2 | 0.030 |
Why?
| | Odontoid Process | 1 | 1995 | 5 | 0.030 |
Why?
| | Cross-Sectional Studies | 2 | 2015 | 4410 | 0.030 |
Why?
| | Chemokines | 1 | 2017 | 216 | 0.030 |
Why?
| | Equipment Contamination | 1 | 2016 | 54 | 0.030 |
Why?
| | Chondrosarcoma | 1 | 1995 | 12 | 0.030 |
Why?
| | Atlanto-Axial Joint | 1 | 1995 | 12 | 0.030 |
Why?
| | Surgical Wound Dehiscence | 1 | 1995 | 19 | 0.030 |
Why?
| | Chordoma | 1 | 1995 | 11 | 0.030 |
Why?
| | Respiratory Mucosa | 1 | 2018 | 251 | 0.030 |
Why?
| | Spinal Neoplasms | 1 | 1995 | 28 | 0.030 |
Why?
| | Water Microbiology | 1 | 2016 | 77 | 0.030 |
Why?
| | Spinal Diseases | 1 | 1995 | 39 | 0.030 |
Why?
| | Thyroid Neoplasms | 1 | 1998 | 264 | 0.030 |
Why?
| | Tracheostomy | 1 | 1996 | 101 | 0.030 |
Why?
| | Biological Products | 1 | 2018 | 166 | 0.030 |
Why?
| | Joint Dislocations | 1 | 1995 | 57 | 0.030 |
Why?
| | Esophageal Neoplasms | 1 | 1998 | 273 | 0.030 |
Why?
| | Drug Therapy, Combination | 1 | 2018 | 951 | 0.030 |
Why?
| | Postoperative Hemorrhage | 1 | 1995 | 74 | 0.030 |
Why?
| | Joint Diseases | 1 | 1995 | 59 | 0.030 |
Why?
| | RNA, Bacterial | 1 | 2016 | 174 | 0.030 |
Why?
| | Acquired Immunodeficiency Syndrome | 1 | 1996 | 217 | 0.030 |
Why?
| | Drug Hypersensitivity | 1 | 2016 | 83 | 0.030 |
Why?
| | Sweat | 1 | 2014 | 38 | 0.030 |
Why?
| | Adrenal Cortex Hormones | 1 | 2018 | 497 | 0.030 |
Why?
| | Perioperative Care | 1 | 2015 | 127 | 0.030 |
Why?
| | Allergens | 1 | 2018 | 413 | 0.030 |
Why?
| | Environmental Exposure | 1 | 2018 | 372 | 0.030 |
Why?
| | Nutritional Status | 1 | 1996 | 287 | 0.030 |
Why?
| | Reproducibility of Results | 2 | 2003 | 2765 | 0.030 |
Why?
| | Socioeconomic Factors | 1 | 2018 | 1079 | 0.030 |
Why?
| | Chlorides | 1 | 2014 | 127 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2016 | 485 | 0.030 |
Why?
| | Vestibulocochlear Nerve | 1 | 1993 | 6 | 0.030 |
Why?
| | Immunoglobulin G | 1 | 2017 | 770 | 0.030 |
Why?
| | Intubation, Intratracheal | 1 | 1995 | 216 | 0.030 |
Why?
| | Facial Nerve | 1 | 1993 | 31 | 0.030 |
Why?
| | Phospholipase C beta | 1 | 2013 | 25 | 0.030 |
Why?
| | Cranial Nerve Diseases | 1 | 1993 | 42 | 0.030 |
Why?
| | Risk Factors | 2 | 2018 | 8632 | 0.030 |
Why?
| | Transducin | 1 | 2013 | 40 | 0.030 |
Why?
| | Drug Resistance | 1 | 2013 | 158 | 0.030 |
Why?
| | Pseudomonas Infections | 1 | 2014 | 184 | 0.030 |
Why?
| | Olfaction Disorders | 1 | 2013 | 50 | 0.030 |
Why?
| | Angiography | 1 | 2013 | 174 | 0.030 |
Why?
| | Surgical Wound Infection | 1 | 2015 | 248 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2013 | 305 | 0.030 |
Why?
| | Laryngoscopy | 1 | 2013 | 91 | 0.030 |
Why?
| | Gene Expression | 1 | 2017 | 1421 | 0.030 |
Why?
| | Respiratory Tract Diseases | 1 | 2013 | 138 | 0.020 |
Why?
| | Epithelium | 1 | 2013 | 295 | 0.020 |
Why?
| | Disease-Free Survival | 1 | 2013 | 620 | 0.020 |
Why?
| | Hematoma | 1 | 2011 | 49 | 0.020 |
Why?
| | Animals | 1 | 2012 | 31708 | 0.020 |
Why?
| | Eosinophils | 1 | 2013 | 278 | 0.020 |
Why?
| | Blood Loss, Surgical | 1 | 2011 | 84 | 0.020 |
Why?
| | Receptors, G-Protein-Coupled | 1 | 2013 | 194 | 0.020 |
Why?
| | Survival Rate | 1 | 1995 | 1644 | 0.020 |
Why?
| | Phenylephrine | 1 | 2011 | 71 | 0.020 |
Why?
| | Academic Medical Centers | 1 | 2013 | 411 | 0.020 |
Why?
| | Data Collection | 1 | 2013 | 620 | 0.020 |
Why?
| | Down Syndrome | 1 | 1995 | 335 | 0.020 |
Why?
| | Precision Medicine | 1 | 2014 | 337 | 0.020 |
Why?
| | Administration, Topical | 1 | 2011 | 138 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2017 | 1518 | 0.020 |
Why?
| | Combined Modality Therapy | 1 | 1993 | 1121 | 0.020 |
Why?
| | Survival Analysis | 1 | 2013 | 1211 | 0.020 |
Why?
| | Cytokines | 1 | 2018 | 1841 | 0.020 |
Why?
| | Neoplasm Staging | 1 | 2013 | 1167 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2013 | 993 | 0.020 |
Why?
| | Workload | 1 | 2011 | 132 | 0.020 |
Why?
| | Societies, Medical | 1 | 2013 | 664 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2013 | 1083 | 0.020 |
Why?
| | Career Choice | 1 | 2011 | 177 | 0.020 |
Why?
| | Residence Characteristics | 1 | 2011 | 275 | 0.020 |
Why?
| | Logistic Models | 1 | 2013 | 1841 | 0.020 |
Why?
| | Biomarkers | 1 | 2017 | 3408 | 0.020 |
Why?
| | Pain | 1 | 2013 | 705 | 0.020 |
Why?
| | Arthritis, Rheumatoid | 1 | 1995 | 1003 | 0.020 |
Why?
| | Clinical Trials as Topic | 1 | 2011 | 932 | 0.020 |
Why?
| | Skin Neoplasms | 1 | 1993 | 756 | 0.020 |
Why?
| | Frontal Sinusitis | 1 | 2005 | 3 | 0.020 |
Why?
| | Practice Patterns, Physicians' | 1 | 2013 | 1177 | 0.020 |
Why?
| | Prostatic Neoplasms | 1 | 2012 | 921 | 0.010 |
Why?
| | Clinical Competence | 1 | 2011 | 893 | 0.010 |
Why?
| | Lung | 1 | 1996 | 3561 | 0.010 |
Why?
| | Cohort Studies | 1 | 2013 | 4895 | 0.010 |
Why?
| | Postoperative Care | 1 | 2005 | 222 | 0.010 |
Why?
| | Surveys and Questionnaires | 1 | 2013 | 4623 | 0.010 |
Why?
| | Adipose Tissue | 1 | 2005 | 545 | 0.010 |
Why?
| | Facial Pain | 1 | 2001 | 11 | 0.010 |
Why?
| | Masks | 1 | 2001 | 46 | 0.010 |
Why?
| | Exophthalmos | 1 | 2001 | 19 | 0.010 |
Why?
| | Nasal Obstruction | 1 | 2001 | 22 | 0.010 |
Why?
| | Phantoms, Imaging | 1 | 2001 | 123 | 0.010 |
Why?
| | Radiography, Interventional | 1 | 2001 | 104 | 0.010 |
Why?
| | Headache | 1 | 2001 | 133 | 0.010 |
Why?
| | Infant | 1 | 2011 | 7964 | 0.010 |
Why?
| | Laryngectomy | 1 | 1998 | 13 | 0.010 |
Why?
| | Sensitivity and Specificity | 1 | 2003 | 1693 | 0.010 |
Why?
| | Radiosurgery | 1 | 2001 | 299 | 0.010 |
Why?
| | Algorithms | 1 | 1998 | 1469 | 0.010 |
Why?
|
|
Kingdom's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|